Heuft H G, Dubiel M, Kingreen D, Oertel J, De Reys S, Rick O, Serke S, Schwella N
Blood Bank and Division of Hematology/Oncology, Department of Internal Medicine, Charité University Hospital/Virchow Clinic, Humboldt University, Berlin, Germany.
Vox Sang. 2000;79(2):94-9. doi: 10.1159/000031219.
A convenient, effective and safe peripheral blood stem cell (PBSC) apheresis procedure is desirable to cope with the increasing requirements for PBSC collections. We performed PBSC harvesting with the novel COBE Spectra AutoPBSC(TM) system using the default software configuration recommended by the manufacturer. We analyzed collection parameters and clinical efficiency of harvested autografts following high-dose chemotherapy (HDCT).
Eighty-one patients underwent 102 harvests after standard chemotherapy plus filgrastim (5-10 microg/kg/day) to obtain a target of >/=2.5 x 10(6) CD34+ cells/kg for autologous blood stem cell transplantation. Conventional-volume leukaphereses (median: 11 liters) were performed using the manufacturer's standard software default regarding inlet flow, harvest/chase volume (3/7 ml) and number of collection cycles. The ratio of ACD-A to whole blood was initially set at 1:12 (56 collections), later at 1:10 (46 aphereses).
With respect to preapheresis counts of 93 (9-876) CD34+ cells/microl, 69 patients (85.2%) achieved >/=2.5 x 10(6) CD34+ cells/kg by the first apheresis. PBSC products contained medians of 5.0 x 10(6) (0.7-77.3) CD34+ cells/kg and 13.8 x 10(4) (2.3-105.0) CFU-GM/kg. A preapheresis count of >/=40 CD34+ cells/microl predicted a single-apheresis yield of >/=2.5 x 10(6) CD34+ cells/kg. Apheresis products showed a high mononuclear cell (MNC) purity of >/=89%. The median overall collection efficiency of CD34+ cells (CD34-CE) was 42.6% (12.2-87.4). The CD34-CE decreased significantly with increasing numbers of circulating CD34+ cells: 52.5% at CD34+ cells <40/microl versus 41.0% at CD34+ cells >/=40/microl (p </= 0. 002). Coagulation problems occurred in 3 of 56 procedures at an ACD-A to whole blood ratio of 1:12, but in no case at 1:10. Patients who underwent HDCT and autologous blood stem cell transplantation (n = 40) engrafted in a median time of 9 (8-13) days for absolute neutrophil counts >0.5 x 10(3)/microl, 10 (8-13) days for WBC >1.0 x 10(3)/microl and 11 (8-17) days for platelets >20 x 10(3)/microl.
As a result of efficient PBSC mobilization, a single conventional-volume leukapheresis with the COBE Spectra AutoPBSC system resulted in hematopoietic autografts with >/=2.5 x 10(6) CD34+ cells/kg in 85% of patients. Following the standard PBSC apheresis recommendations of the manufacturer, the AutoPBSC system assures PBSC products with a high MNC purity and a moderate CD34-CE that declines significantly at increasing levels of circulating CD34+ cells. Leukaphereses performed at an ACD-A to whole blood ratio of 1:10 should run without coagulation problems.
为满足外周血干细胞(PBSC)采集需求的不断增加,需要一种方便、有效且安全的PBSC采集程序。我们使用制造商推荐的默认软件配置,通过新型COBE Spectra AutoPBSC(TM)系统进行PBSC采集。我们分析了大剂量化疗(HDCT)后采集的自体移植物的采集参数和临床效率。
81例患者在接受标准化疗加非格司亭(5 - 10微克/千克/天)后进行了102次采集,以获得≥2.5×10⁶个CD34⁺细胞/千克的目标用于自体造血干细胞移植。使用制造商标准软件默认设置,进行常规体积的白细胞单采(中位数:11升),涉及进样流速、采集/冲洗体积(3/7毫升)和采集周期数。ACD - A与全血的比例最初设定为1:12(56次采集),之后设定为1:10(46次单采)。
对于采集前CD34⁺细胞计数为93(9 - 876)个/微升的情况,69例患者(85.2%)通过首次采集达到≥2.5×10⁶个CD34⁺细胞/千克。PBSC产品中CD34⁺细胞中位数为5.0×10⁶(0.7 - 77.3)个/千克,CFU - GM中位数为13.8×10⁴(2.3 - 105.0)个/千克。采集前CD34⁺细胞计数≥40个/微升可预测单次采集产量≥2.5×10⁶个CD34⁺细胞/千克。单采产品显示单核细胞(MNC)纯度高,≥≥89%。CD34⁺细胞的总体采集效率中位数(CD34 - CE)为42.6%(12.2 - 87.4)。随着循环CD34⁺细胞数量增加,CD34 - CE显著下降:CD34⁺细胞<40个/微升时为52.5%,而CD34⁺细胞≥40个/微升时为41.0%(p≤0.002)。在ACD - A与全血比例为1:12的56次操作中,有3次出现凝血问题,但在比例为1:10时未出现。接受HDCT和自体造血干细胞移植的患者(n = 40),中性粒细胞绝对计数>0.5×10³/微升的中位植入时间为9(8 - 13)天,白细胞>1.0×10³/微升的中位植入时间为10(8 - 13)天,血小板>20×10³/微升的中位植入时间为11(8 - 17)天。
由于有效的PBSC动员,使用COBE Spectra AutoPBSC系统进行单次常规体积白细胞单采,85%的患者获得了≥2.5×10⁶个CD34⁺细胞/千克的造血自体移植物。遵循制造商的标准PBSC单采建议,AutoPBSC系统可确保PBSC产品具有高MNC纯度和适度的CD34 - CE,且随着循环CD34⁺细胞水平升高,CD34 - CE会显著下降。以1:10的ACD - A与全血比例进行白细胞单采应不会出现凝血问题。